newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - BIOAGE LABS INC

  • Financial Performance:

    • Holds approximately $350 million in cash, providing a runway through 2029.
    • Current capital is allocated to fund the BGE-102 Phase 2 trial (QUAL-CV and Quell-DME), APJ agonist development through proof of concept, and potential additional NLRP3 indications.
  • Guidance and Future Outlook:

    • BGE-102 Phase 2 data readout expected by the end of the current year.
    • Quell-DME (Diabetic Macular Edema) Phase 2 readout projected for the second half of next year.
    • IND filing for the first APJ agonist program targeted by the end of the year.
    • Strategic focus shifts immediately toward ophthalmology and other de-risked indications, with cardiovascular outcomes trials deferred pending clearer signals from competitors (e.g., Artemis trial results).
  • Business Segments and Product Lines:

    • Lead Program (BGE-102): Oral NLRP3 inhibitor with a novel binding site (distinct from ATPase pocket competitors); demonstrated 98% trough IL-1β suppression with placebo-like tolerability in Phase 1; high tissue distribution profile enables CNS and retinal penetration.
    • Ophthalmology Strategy: Quell-DME trial evaluating BGE-102 as monotherapy and in combination with VEGF; aims to offer an oral alternative to intravitreal injections for patients resistant to injections or with incomplete VEGF control.
    • Obesity/Longevity (APJ Agonists): Two programs (oral and parenteral) targeting Apelin Receptor; preclinical data suggests potential to double weight loss and restore body composition when combined with GLP-1s.
    • Platform Partnerships: Collaboration with Lilly for therapeutic antibody development and with Novartis for target discovery linking aging biology, exercise benefits, and healthy longevity.
  • Market and Competitive Landscape:

    • NLRP3 Competition: Differentiated by novel binding site and ability to trigger inflammasome disassembly, contrasting with competitors targeting the same ATPase pocket; ZILTI (IL-6) trial failure reinforces the potential superiority of upstream NLRP3 targeting.
    • Ophthalmology Market: Addresses significant patient resistance to intravitreal injections (40% in "watch and wait" category) and offers a potential solution for VEGF-refractory patients.
    • Obesity Market: Positioning APJ agonists as a weight-loss and muscle-preserving modality, capitalizing on high unmet need for mechanisms that preserve physical function.
  • Risks and Challenges:

    • Strategic Pivot Risk: Abandoning near-term cardiovascular outcomes trials (ASCVD) delays potential blockbuster revenue; strategy depends on competitor data (e.g., Ventix, Artemis) validating the approach.
    • Clinical Execution: Dependence on upcoming Phase 2 data to validate dose-response relationships and biomarker reductions; failure in Quell-DME could limit the ophthalmology beachhead.
    • Safety Concerns: Previous APJ program faced liver safety signals; new programs utilize distinct chemotypes and lower dosing targets (<100mg) to mitigate idiosyncratic liver injury risks.
  • Management Commentary and Tone:

    • Tone is confident regarding the scientific differentiation of BGE-102's unique binding mechanism and deep target inhibition.
    • Management demonstrates pragmatism in pivoting away from high-risk, high-cost cardiovascular outcomes trials in the current capital environment, favoring indications with shorter timelines and de-risked biology.
    • Emphasis on the "beachhead" strategy in ophthalmology to leverage the oral delivery advantage and tissue penetration.
  • Analyst Questions and Answers:

    • Differentiation vs. Competitors: Confirmed unique binding site prevents cross-resistance and enables deeper inhibition compared to historical chemotypes; Phase 1 data shows superior biomarker suppression (86% CRP reduction).
    • Impact of ZILTI Failure: Concluded that IL-6 is likely too downstream and a biomarker rather than a causal driver, reinforcing the strategic choice to target upstream NLRP3.
    • DME Trial Design: Modeled after successful IL-6 trials (e.g., Mickey Bar) to show efficacy in 3 months; powered for 4-letter improvement in BCVA (better than the standard 1-line goal).
    • APJ Safety: Clarified that the new program uses a completely novel chemotype and lower doses to avoid the liver toxicity seen in the prior Amgen-licensed program.
  • Other Key Points:

    • BGE-102 is being evaluated in cohorts with obesity and elevated inflammation to assess metabolic benefits (liver fat, glucose control) alongside cardiovascular markers.
    • Future NLRP3 pipeline may include Geographic Atrophy (GA) and Uveitic Macular Edema, following the de-risking of DME.
    • The company's aging platform utilizes 50-year longitudinal data from global biobanks to identify longevity and physical function biomarkers.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC